• News
  • SAN DIEGO
  • BioTech

Mast Therapeutics reports 2Q net loss

San Diego-based Mast Therapeutics Inc. (NYSE: MSTX) reported a second quarter net loss of $7.2 million, or $0.06 per share, compared to a net loss of $4.9 million, or $0.09 per share, for the same period in 2013.

The company also reported a net loss for the six months ending June 30, 2014 of $13.5 million, or $0.12 per share, compared to a net loss of $10.5 million, or $0.21 per share, for the same period in 2013.

The company had cash, cash equivalents and investment securities totaling $46.4 million as of June 30. Stockholders' equity amounted to $50.2 million as of June 30.

“This is an important time for Mast,” said Brian M. Culley, the company’s CEO. “We have an ongoing Phase 3 study in a rare disease with more than an 18-month head start on our nearest competitor.”

The company also has a Phase 2 study planned in heart failure and has funds to move these and our other programs toward major value inflection points, according to Culley.

User Response
0 UserComments

Mast Therapeutics Inc.

Company Website

12390 El Camino Real Ste., 150
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
MSTX
0.5
  -0.01  
- 1.96%
703,889,000
0.63
0.38

Mast Therapeutics Inc. Executive(s):

Brian Culley

  • Chief Executive Officer

Patrick Keran

  • Chief Operating Officer, President

Brandi Roberts

  • Chief Financial Officer